

# The Pediatric Infectious Disease Journal

## Linezolid for children with tuberculous meningitis: more evidence required.

--Manuscript Draft--

<b>Manuscript Number:</b>	PIDJ-216-716
<b>Full Title:</b>	Linezolid for children with tuberculous meningitis: more evidence required.
<b>Article Type:</b>	Letter to the Editor
<b>Keywords:</b>	Tuberculosis Meningitis Linezolid
<b>Corresponding Author:</b>	Robindra Basu Roy, MRCPCH Imperial College London London, UNITED KINGDOM
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Imperial College London
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Robindra Basu Roy, MRCPCH
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Robindra Basu Roy, MRCPCH James A Seddon, PhD
<b>Order of Authors Secondary Information:</b>	
<b>Manuscript Region of Origin:</b>	UNITED KINGDOM

Linezolid for children with tuberculous meningitis: more evidence required

Robindra Basu Roy, MRCPCH & James A. Seddon, PhD

Department of Academic Paediatrics  
Imperial College London

Corresponding Author:

Dr. R. Basu Roy  
Department of Academic Paediatrics  
2<sup>nd</sup> Floor, Medical School Building  
St. Mary's Campus  
Imperial College London  
Norfolk Place  
London  
W2 1PG  
United Kingdom

r.basu-roy@imperial.ac.uk  
Tel: +4420 7594 8839  
Fax: +4420 7594 3984

Funding:

R Basu Roy is a Clinical Research Training Fellow jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and this funding is also part of the EDCTP2 programme supported by the European Union. (MR/K023446/1).

JA Seddon is an Academic Clinical Lecturer funded by the National Institute of Health Research, and also the recipient of a Starter Grant from the Academy of Medical Sciences (AMS-SGCL11-Seddon).

Conflicts of Interest: None.

Keywords: Linezolid, Tuberculosis, Meningitis

A Letter to the Editor in response to:

Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is Associated with Improved Early Outcomes of Childhood Tuberculous Meningitis. *Pediatr Infect Dis J*. 2016 Jun;35(6):607–10.

To the editors:

1  
2  
3  
4  
5 Tuberculous meningitis (TBM) is a devastating disease. With the currently available  
6  
7 treatment regimens one in five children die and only a third of surviving children  
8  
9 escape neurological sequelae.<sup>1</sup> If there was any way of improving these outcomes  
10  
11 significant mortality and morbidity would be averted. We were greatly interested,  
12  
13 therefore, to read the study by Li *et al* regarding the use of linezolid in children with  
14  
15 TBM in Beijing.<sup>2</sup>  
16  
17  
18  
19  
20

21  
22 In many ways linezolid is an attractive therapeutic option given its good  
23  
24 bioavailability, excellent CSF penetration and proven efficacy against *M.*  
25  
26 *tuberculosis*. However, three major obstacles currently limit the use of linezolid in the  
27  
28 treatment of pediatric TBM: efficacy, safety and current high cost. Until this report the  
29  
30 only described use of linezolid in pediatric TBM had been in the successful treatment  
31  
32 of a South African case of extensively drug-resistant TBM.<sup>3</sup>  
33  
34  
35  
36  
37

38  
39 Caution is warranted in interpreting the efficacy of linezolid in the treatment of  
40  
41 pediatric TBM from this report. The retrospective design, unrandomised nature of  
42  
43 group allocations, and unblinded ascertainment of outcomes limit how much can be  
44  
45 inferred. In terms of patient selection, children were given linezolid if they remained  
46  
47 febrile after two weeks on conventional treatment and had no neurological  
48  
49 improvement in that time. It is therefore unclear why over 50% of children in the  
50  
51 control group had a fever clearance time of greater than 4 weeks. It would be useful  
52  
53 for the authors to further clarify on what criteria the decision to use linezolid was  
54  
55 made, and from what common reference point during therapy fever clearance time  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 comparisons were made. Persistent fever following initiation of anti-tuberculous  
2 therapy with confirmed drug susceptible strains of *M. tuberculosis* is a recognized,  
3  
4 although unusual, clinical phenomenon.<sup>4</sup>  
5  
6  
7  
8

9 It would also be important to know if the improved outcomes were due to linezolid  
10 improving the treatment of TBM generally, or if the advantage was the result of  
11 improved treatment in cases with drug resistance. Understanding this would allow  
12 clinicians to evaluate whether this drug should be reserved only for cases with drug  
13 resistance. It would therefore be interesting to know if there are any molecular or  
14 phenotypic drug resistance results available from either the 14 microbiologically  
15 confirmed TB cases, or from the TB source cases identified in 50 of the children.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 Regarding safety, the authors report no significant difference in adverse events (GI  
30 disturbance, hepatotoxicity, rash, peripheral neuropathy or thrombocytopenia)  
31 between the 36 children treated with linezolid and those who received standard  
32 treatment. However, it is unclear from the report how the children were evaluated for  
33 these and whether they may have experienced any other side effects (such as lactic  
34 acidosis, optic neuropathy, impaired renal function, raised amylase or  
35 hypoglycemia<sup>5</sup>).  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 We commend the authors on reporting these cases and providing some much-  
49 needed data where so little exists. We look forward to learning from their  
50 experiences in even more depth. In our opinion however, there is currently still  
51 insufficient evidence to warrant use of linezolid in paediatric TBM without information  
52 strongly suggestive of drug resistance.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1. Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2014 Oct;14(10):947–57.
2. Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is Associated with Improved Early Outcomes of Childhood Tuberculous Meningitis. *Pediatr Infect Dis J.* 2016 Jun;35(6):607–10.
3. Alsleben N, Garcia-Prats AJ, Hesselning AC, Willemse M, Donald PR, Schaaf HS. Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis. *J Pediatric Infect Dis Soc.* 2015 Sep;4(3):e41–4.
4. Coulter JBS, Baretto RL, Mallucci CL, Romano MI, Abernethy LJ, Isherwood DM, et al. Tuberculous meningitis: protracted course and clinical response to interferon-gamma. *Lancet Infectious Diseases.* 2007. p. 225–32.
5. Viswanathan P, Iarikov D, Wassel R, Davidson A, Nambiar S. Hypoglycemia in patients treated with linezolid. *Clin Infect Dis.* 2014 Oct 15;59(8):e93–5.